

Condylomata acuminata, Bowenoid papulosis, and squamous cell carcinoma, all positive for human papillomavirus type 16/18 DNA, coexisting in the genital area: a case report*

Efstathia Pasmatzī¹✉, George Badavanis¹, Nikiforos Kapranos², Alexandra Monastirli¹, Assimina Apostolidou¹, Dionysios Tsambaos¹

¹Department of Dermatology, School of Medicine, University of Patras, Patras, Greece. ²Laboratory for Molecular Histopathology, Athens, Greece.

Abstract

In an attempt to raise awareness among physicians of the importance of early diagnosis and treatment of penile cancer and its precursor lesions, we report the unique case of a male patient with condylomata acuminata, Bowenoid papulosis, and squamous cell carcinoma, all HPV 16/18–positive, coexisting in his genital area.

Keywords: human papillomavirus, condyloma acuminatum, Bowenoid papulosis, squamous cell carcinoma

Received: 8 March 2021 | Returned for modification: 16 June 2021 | Accepted: 23 June 2021

Introduction

Human papillomaviruses (HPVs) constitute a large and heterogeneous group of non-enveloped small circular double-stranded DNA viruses with a life cycle closely associated with keratinocytes undergoing terminal differentiation (1). HPVs affect the stratified squamous epithelia of the skin and cause a large spectrum of benign and malignant mucocutaneous disorders (2).

More than 200 HPV types have been identified so far (3). Among them, about 50 are capable of affecting the genital tract in both sexes, being classified as “low-risk” and “high-risk” according to the degree of their oncogenic potential (4). Thus, “low-risk” HPV types are thought to cause mostly benign clinical manifestations, whereas “high-risk” ones are associated with anogenital cancer (5, 6).

Genital HPV infection in men is the most common sexually transmitted disease; it occurs on the penis of 16 to 69% of healthy men (depending on the methodology applied and the population studied) and may progress to clinical manifestations that are classified into three distinct groups: a) condylomata acuminata, b) penile intraepithelial neoplasia (PIN), which encompasses three clinically distinct variants (Bowenoid papulosis, or BP; erythroplasia of Queyrat, or EQ; and Bowen’s disease, or BD, sharing the histological features of squamous cell carcinoma, or SCC, in situ), and c) SCC (7, 8).

We report herein the first case of coexisting condylomata acuminata, BP, and SCC, all HPV 16/18–positive, in the genital area of a male patient.

Case report

A 62-year-old Caucasian, heterosexual, HIV-negative man presented to the Department of Dermatology at the Patras University Medical Center with quite a remarkable 6-year history of “warts” in the genital area. Because some of the initial lesions disappeared within several months, the patient thought that all the lesions would resolve over time; therefore he did not seek any medical advice and care. However, not only did the skin lesions show

no sign of resolution, but they progressively increased in number and size. About 2 years prior to the patient’s presentation, a pre-existing lesion on the penis shaft started growing rapidly and progressively transformed into an extensive ulcer. It was only when this penile lesion showed extreme deterioration that the patient managed to overcome his fear and shame and seek medical help. He had a history of diabetes mellitus, hypertension, and hyperlipidemia, but no history or evidence of infectious, autoimmune, or neoplastic disorders.

Physical examination revealed the following clinical manifestations (Fig. 1): 1) several small flesh-colored papules on the left




Figure 1 | Small flesh-colored papules on the left inguinal area (condylomata acuminata, CA); multiple reddish-gray shiny papules coalescing into two annular plaques located on the subscrotal area (Bowenoid papulosis, BP); a large, multinodular, erosive, hemorrhagic, and locally destructive mass that affects the penis shaft, producing a yellowish discharge (squamous cell carcinoma, SCC).

✉ Corresponding author: pasmatzi@otenet.gr; efipas@upatras.gr

*Dedicated to the memory of Professor Dr. John Varakis, Department of Anatomy, School of Medicine, University of Patras, Patras, Greece.

inguinal area, 2) multiple reddish-gray shiny papules coalescing into two annular plaques located on the subscrotal area, 3) a large, multinodular, erosive, hemorrhagic, and locally destructive mass on the penis shaft producing a yellowish discharge, and 4) large and indurated inguinal and axillary lymph nodes.

Microbiological examination of secretion samples derived from the lesion on the penis shaft revealed the presence of *Proteus vulgaris* and *Serratia marcescens*. Based on the results of the antibiogram, the patient was given a 14-day course of intravenous administration of ciprofloxacin (500 mg \times 2/day) and clindamycin (400 mg \times 3/day), which led to a complete resolution of inflammation and exudate.

Routine laboratory tests, including a complete blood count, blood chemistry, urinalysis, and immunological and serological investigations—tests for syphilis, herpes simplex virus 1 and 2 (HSV 1 & 2), human immunodeficiency virus 1 and 2 (HIV 1 & 2), hepatitis A, B, and C, and cytomegalovirus (CMV)—were either negative or within normal limits. Chest X-ray and bone scanning investigations, electrocardiogram, and colonoscopy were unremarkable. Whole-body computer tomography (CT) revealed large inguinal, axillary, and paratrachial lymph nodes and right pleura thickening.

Histological examination of skin biopsy specimens obtained from the lesions on the left inguinal area, the subscrotal region, and the penis shaft revealed the features of condylomata acuminata, BP, and SCC respectively (Figs. 2a–c). *In situ* hybridization performed on routinely formalin-fixed and paraffin-embedded specimens using commercially available biotinylated HPV-DNA probes (Rembrandt Kit, PanPath, Amsterdam, Netherlands) revealed the presence of HPV types 16/18 in the nuclei of keratinocytes in all lesions (Figs. 2d–f).

Because we informed the patient about the results of the histopathological, imaging, and routine laboratory investigations performed and suggested urgent surgical intervention, he requested his transfer to the urology department at a hospital in his hometown, where he underwent a radical penectomy, after which he was lost to follow up.

Discussion

Condylomata acuminata are the most common clinical manifestation of HPV infection that primarily involves the skin and mucosae of the anogenital region, affecting about 1% of sexually active adults worldwide with increasing incidence (9, 10). Condylomata




Figure 2 | Condylomata acuminata: (A) histological section showing orthokeratosis and epidermal hyperplasia with papillomatosis, acanthosis, and koilocytes in the granular and the upper spinous layer (H&E, original magnification 100 \times); (B) hybridization *in situ* showing clear positivity for HPV types 16/18 in many epidermal cell nuclei (DAB/oxidase, original magnification 100 \times); Bowenoid papulosis: (C) histological section showing full thickness replacement of epidermis by large dyskeratotic or atypical cells with loss of polarity and atypical mitoses (H&E, original magnification 400 \times); (D) hybridization *in situ* showing rare, and mostly superficial intranuclear epidermal cell positivity for HPV types 16/18 (DAB/oxidase, original magnification 400 \times); squamous cell carcinoma: (E) histological section showing squamous cells with eosinophilic cytoplasm, severe nuclear atypia, and many mitoses; keratin pearl formation is not evident (H&E, original magnification 400 \times); (F) hybridization *in situ* for HPV types 16/18. The signal is localized in almost all neoplastic cell nuclei and has the form of intranuclear dots, suggesting integration of HPV DNA in the host cell genome (DAB/oxidase, original magnification 600 \times).

acuminata are acquired through sexual contact with an affected person and are highly infectious, with a transmission rate of about 65% (11, 12). In uncircumcised men, condylomata acuminata most commonly affect the glans penis, coronal sulcus, preputial cavity, and frenulum, whereas in circumcised men they mostly occur on the penile shaft (13).

Clinically, they are characterized by usually asymptomatic flesh-colored, red, or brown, solitary or confluent, smooth-surfaced or warty papules, and their histological features include acanthosis, parakeratosis, koilocytosis, and papillomatosis. In about 30% of clinically evident condylomata acuminata, spontaneous regression can occur within 12 to 24 months, whereas in other cases condylomata acuminata may persist for months or years and occasionally progress to intraepithelial neoplasia or even to life-threatening invasive SCC, as reported for the first time by Buschke and Loewenstein (1931) 90 years ago (14, 15).

In immunocompromised individuals (e.g., HIV-infected patients and organ transplant recipients), condylomata acuminata are more often seen (compared to healthy individuals), occur even in unusual localizations, and reveal a high tendency to recurrence and malignant transformation (16). In up to 95% of condylomata acuminata cases, HPV types 6 and 11 are the main etiological agents of the disease; in rare instances, however, other HPV types, even high-risk ones, are also implicated in the mechanisms of the development of condylomata acuminata (Table 1) (13, 17, 18, 38–46).

In 1970, Lloyd (19) was the first to describe an uncommon skin condition primarily affecting the anogenital area of sexually active individuals that was characterized by pink, red, or brown, solitary or confluent verrucous papules. These lesions clinically resembled those of condylomata acuminata or lichen planus and were histologically similar to BD (19). Several years later, Wade et al. (20) recognized this disorder as a distinct nosological entity, for which they introduced the term *Bowenoid papulosis* (BP). This was previously regarded as a benign disorder, which in immunocompetent individuals occasionally reveals spontaneous regression; however, today it is well known that BP is a variant of high-grade intraepithelial neoplasia or SCC *in situ* caused by HPV infection that, if left untreated, may progress to BD and invasive SCC after some years of persistence (21, 22). BP is primarily due to HPV16 and/or HPV18 infection, with a prevalence of up to 69.2%, and less frequently due to a variety of other HPV types, as shown in Table 1 (23, 24, 47–54).

Penile carcinoma is a relatively rare and devastating tumor that predominantly affects elderly men. It has the highest incidence between 50 and 70 years of age and accounts for 0.3 to 0.5% of all male malignancies in Europe and the United States (25–27). SCC represents 95% of all penile carcinomas and usually originates from the epithelium of the inner prepuce and glans and less often on the penile shaft; its invasive form manifests as a painful ulcerative and/or papillary lesion, which progressively grows and

is associated with discharge, bleeding, or foul odor (28).

Penile SCC may develop either *de novo* or subsequent to malignant transformation of precursor lesions. Recent epidemiological studies have shown that the occurrence of penile SCC is related to HPV infection and multiple risk factors; thus, two major causative pathways are thought to be implicated in penile SCC development: a) the HPV-associated pathway, probably involving sexual contact, and b) a non-HPV-associated pathway related to risk factors such as lack of circumcision in childhood, cigarette smoking, phimosis, poor penile hygiene and trauma, multiple sexual partners, balanitis xerotica obliterans, lichen sclerosus et atrophicans, and ultraviolet A phototherapy of the genital area (15, 29–32).

In view of these pathways, penile carcinomas are classified by the Union for International Cancer Control (UICC) into HPV-associated and non-HPV-associated (33). The reported overall prevalence of HPV infection in penile SCC varies between 11.6 and 100% due to the heterogeneity of this tumor and differences between the studies performed with regard to the methodology applied and the characteristics of the populations studied (34, 35). The following histologic subtypes of HPV-associated penile SCCs are recognized: basaloid, papillary basaloid, warty, warty basaloid, clear-cell, and lymphoepithelioma-like carcinoma, with the basaloid and warty penile SCC subtypes showing the strongest HPV-association (13, 36). Worldwide, HPV 16 (followed by HPV 18 and HPV 6) is identified in the majority of HPV-mediated penile SCCs (34, 35) irrespective of geographic area, whereas on some occasions other HPV-genotypes are also etiologically implicated in the pathogenesis of these tumors, as shown in Table 1 (55–61).

Although the exact mechanisms underlying HPV-induced penile carcinogenesis are still far from being clearly understood, there is no doubt that viral oncoproteins E6 and E7 transcribed in HPV-affected epithelial cells play a critical role in this process. Indeed, apart from their disruptive effects on centrosome synthesis (6), viral E6 and E7 oncoproteins target tumor protein 53 (p53) and retinoblastoma 1 (RB1) tumor suppressor proteins, respectively, which negatively regulate the mitotic activity of the affected cells, resulting in uncontrolled cell cycle progression and an inhibition of DNA repair and apoptosis (26, 37).

To the best of our knowledge, this is the first time that the coexistence of condylomata acuminata, BP, and SCC in the genital region of a male patient has been reported, with all these disorders being positive for HPV 16/18, as demonstrated by *in situ* hybridization. The possibility that these HPV-associated diseases developed *de novo* independently of each other cannot be definitely ruled out. However, in view of their persistence and long duration as well as the common causative factor (HPV 16/18), which is capable of inducing a neoplastic phenotype in the affected epithelial cells, it seems reasonable to suggest that these lesions are etiologically related to each other and represent clinical manifestations of different stages of a single HPV-related cutaneous carcinogenesis process.

Table 1 | Distribution of HPV types in HPV-associated genital diseases in men.

Disease	Distribution of HPV types*	References
Condylomata acuminata	6, 11 , 16, 18, 30, 31, 32, 33, 34, 35, 39, 40, 41, 42, 43, 44, 45, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 74, 79, 81, 82, 83, 84	13, 17, 18, 38, 39, 40, 41, 42, 43, 44, 45, 46
Bowenoid papulosis	1, 2, 6, 11, 13, 16 , 18 , 31, 32, 33, 34, 35, 39, 42, 43, 44, 51, 52, 53, 58, 67	23, 24, 46, 47, 48, 49, 50, 51, 52, 53, 54
Squamous cell carcinoma	6, 8, 11, 12, 16 , 17, 18 , 20, 23, 31, 32, 33, 34, 35, 39, 40, 44, 45, 51, 52, 56, 58, 59, 66, 68, 70, 73, 74	5, 34, 35, 55, 56, 57, 58, 59, 60, 61

*Numbers in bold represent HPV types with the highest prevalence.

References

1. Doorbar J. The papillomavirus life cycle. *J Clin Virol.* 2005;32:S7–15.
2. Shanmugasundaram S, You J. Targeting persistent human papillomavirus infection. *Viruses.* 2017;9:229.
3. Beziat V. Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis. *Hum Genet.* 2020; 139:919–39.
4. Stanley M. HPV vaccination in boys and men. *Hum Vaccin Immunother.* 2014;10:2109–11.
5. Ljubojevic S, Skerlev M. HPV-associated diseases. *Clin Dermatol.* 2014;32:227–34.
6. Kidd LC, Chaing S, Chipollini J, Giuliano AR, Spiess PE, Sharma P. Relationship between human papillomavirus and penile cancer-implications for prevention and treatment. *Transl Androl Urol.* 2017;6:791–802.
7. Cubilla AL, Velazquez EF, Young RH. Epithelial lesions associated with invasive penile squamous cell carcinoma: a pathologic study of 288 cases. *Int J Surg Pathol.* 2004;12:351–64.
8. Diorio G, Giuliano A. The role of human papilloma virus in penile carcinogenesis and preneoplastic lesions: a potential target for vaccination and treatment strategies. *Urol Clin North Am.* 2016;43:419–25.
9. Brown DR, Bryan JT, Cramer H, Fife KH. Analysis of human papillomavirus types in exo-phytic condylomata acuminata by hybrid capture and Southern blot techniques. *J Clin Microbiol.* 1993;31:2667–73.
10. Scheurer ME, Tortolero-Luna G, Adler-Storzhz K. Human papillomavirus infection: biology, epidemiology, and prevention. *Int J Gynecol Cancer.* 2005;15:727–46.
11. Lacey CJ. Therapy for genital human papillomavirus-related disease. *J Clin Virol.* 2005;32:S82–90.
12. Stanley M. Pathology and epidemiology of HPV infection in females. *Gynecol Oncol.* 2010;117:S5–10.
13. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. *Med Microbiol Immunol.* 2004;193:35–44.
14. Buschke A, Loewenstein L. Beziehungen der spitzen Kondylome zu den Carcinomen des Penis. *Arch Derm Syph.* 1931;163:30–46. German.
15. Anic GM, Giuliano AR. Genital HPV infection and related lesions in men. *Prev Med.* 2011;53:S36–41.
16. Wieland U, Kreuter A. Kondylome bei HIV-Infizierten. *Hautarzt.* 2017;68:192–8. German.
17. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. *Virology.* 2010;401:70–9.
18. Al-Awadhi R, Al-Mutairi N, Albatineh AN, Chehadeh W. Association of HPV genotypes with external anogenital warts: a cross sectional study. *BMC Infect Dis.* 2019;19:375.
19. Lloyd KM. Multicentric pigmented Bowen's disease of the groin. *Arch Dermatol.* 1970;101:48–51.
20. Wade TR, Kopf AW, Ackerman AB. Bowenoid papulosis of the genitalia. *Arch Dermatol.* 1979;115:306–8.
21. Liu H, Urabe K, Moroi Y, Yasumoto S, Kokuba H, Imafuku S, et al. Expression of p16 and hTERT protein is associated with the presence of high-risk human papillomavirus in Bowenoid papulosis. *J Cutan Pathol.* 2006;33:551–8.
22. Brady KL, Mercurio MG, Brown MD. Malignant tumors of the penis. *Dermatol Surg.* 2013;39:527–47.
23. Yoneta A, Yamashita T, Jin HY, Iwasawa A, Kondo S, Jimbow K. Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from Bowenoid papulosis. *Br J Dermatol.* 2000;143:604–8.
24. Liu X, Clements A, Zhao K, Marmorstein R. Structure of the human papillomavirus E7 oncoprotein and its mechanism for inactivation of the retinoblastoma tumor suppressor. *Br Biol Chem.* 2006;6:281:578–86.
25. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. *Vaccine.* 2006; 24 Suppl 3:S311–25.
26. Bleeker MC, Heideman DA, Snijders PJ, Horenblas S, Dillner J, Meijer CJ. Penile cancer: epidemiology, pathogenesis and prevention. *World J Urol.* 2009;27:141–50.
27. Hakenberg OW, Comperat EM, Minhas S, Necchi A, Protzel C, Watkin N. EAU guidelines on penile cancer: 2014 update. *Eur Urol.* 2014;67:142–50.
28. Barocas D, Chang S. Penile cancer: clinical presentation, diagnosis and staging. *Urol Clin N Amer.* 2010;37:343–52.
29. Zhang XH, Sun GQ, Yang Y, Zhang TH. Human papillomavirus and p53 protein immunoreactivity in condylomata acuminatum and squamous cell carcinoma of penis. *Asian J Androl.* 2001;3:75–7.
30. Morris B, Gray R, Castellsaque X, Bosch X, Halperin D, Waskett J, et al. The strong protective effect of circumcision against cancer of the penis. *Adv Urol.* 2011; article ID 812368, doi:10.1155/2011/812368.
31. Stankiewicz E, Prowse D, Ng M, Cuzick J, Mesher D, Hiscock J, et al. Alternative HER/PTEN/Akt pathway activation in HPV positive and negative penile carcinomas. *PLoS One.* 2011;6:e17517.
32. Wattleworth R. HPV infection and the links to penile and cervical cancer. *JAOA.* 2011;111:S3–10.
33. Brierley JD, Gospodarowicz MK, Wittekind C. *TNM classification of malignant tumours.* Chichester, UK: John Wiley & Sons; 2017.
34. Alemany L, Cubilla A, Halc G, Kasamatsu E, Quirós B, Masferrer E, et al. Role of human papillomavirus in penile carcinomas worldwide. *Eur Urol.* 2016;69:953–61.
35. Olesen TB, Sand FL, Rasmussen CL, Albieri V, Toft BG, Norrild B, et al. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. *Lancet Oncol.* 2019;20:145–58.
36. Hakenberg OW, Dräger DL, Erbersdobler A, Naumann CM, Jünemann KP, Protzel C. The diagnosis and treatment of penile cancer. *Dtsch Arztebl Int.* 2018;28; 115:646–52.
37. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. *Cancer Res.* 1996;56:4620–4.
38. Wu XJ, Ren JG, Liu YJ, Liu JL, Wang JJ, Tan PP, et al. Molecular detection of specific HPV types in condylomata acuminata. *Yi Chuan.* 2005;27:699–704.
39. Zhu C, Wang Y, Mao W, Zhang H, Ma J. Prevalence and distribution of HPV types in genital warts in Xi'an, China: a prospective study. *BMJ Open.* 2019;14:e023897.
40. Nadal LR, Saad SS, Lopes Filho G, Joaquim HPG, Manzione TDS, Manzione CR, et al. Comparison between anal cytology, high-resolution anoscopy and HPV DNA genotyping by polymerase chain reaction in the post-treatment follow-up of condylomata acuminata. *Rev Col Bras Cir.* 2020;47:e20202543.
41. Hawkins MG, Winder DM, Ball SL, Vaughan K, Sonnex C, Stanley MA, et al. Detection of specific HPV subtypes responsible for the pathogenesis of condylomata acuminata. *Virol J.* 2013;10:137.
42. Chikandiwa A, Kelly H, Sawadogo B, Ngu J, Pisa PT, Gibson L, et al. Prevalence, incidence and correlates of low risk HPV infection and anogenital warts in a cohort of women living with HIV in Burkina Faso and South Africa. *PLoS One.* 2018;13:e0196018.
43. Anic GM, Lee JH, Stockwell H, Rollison DE, Wu Y, Papenfuss MR, et al. Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study. *J Infect Dis.* 2011;204:1886–92.
44. Turazza EI, Ojeda RD, Ratto P, Barrera A, Ríos A, Kahn T, et al. Identificación de DNA de papilomavirus humano en condilomas anogenitales de una población masculina [DNA identification of human papillomavirus in anogenital condyloma of a male population]. *Medicina (B Aires).* 1993;53:197–201. Spanish.
45. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. *J Clin Microbiol.* 1999;37:3316–22.
46. Cardoso JC, Calonje E. Cutaneous manifestations of human papillomaviruses: a review. *Acta Dermatovenerol Alp Pannonica Adriat.* 2011;20:145–54.
47. Rolighed J, Sørensen IM, Jacobsen NO, Lindeberg H. The presence of HPV types 6/11, 13, 16 and 33 in Bowenoid papulosis in an HIV-positive male, demonstrated by DNA in situ hybridization. *APMIS.* 1991;99:583–5.
48. Pala S, Poleva I, Vocatura A. The presence of HPV types 6/11, 16/18, 31/33/51 in Bowenoid papulosis demonstrated by DNA in situ hybridization. *Int J STD AIDS.* 2000;11:823–4.
49. Guerin-Reverchon I, Chardonnet Y, Viac J, Chouvet B, Chignol MC, Thivolet J. Human papillomavirus infection and flaggrin expression in paraffin-embedded biopsy specimens of extragenital Bowen's disease and genital Bowenoid papulosis. *J Cancer Res Clin Oncol.* 1990;116:295–300.
50. Degener AM, Laino L, Pierangeli A, Accappaticcio G, Innocenzi D, Pala S. Human papillomavirus-32-positive extragenital Bowenoid papulosis (BP) in a HIV patient with typical genital BP localization. *Sex Transm Dis.* 2004;31:619–22.
51. Nayak SU, Shenoi SD, Bhat ST, Shivamurthy A. Bowenoid papulosis. *Indian J Sex Transm Dis AIDS.* 2015;36:223–5.
52. Chamli A, Zaouak A. Bowenoid papulosis. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2021. PMID: 30969709.
53. Papadopoulos AJ, Schwartz RA, Lefkowitz A, Tinkle LL, Jänniger CK, Lambert WC. Extragenital Bowenoid papulosis associated with atypical human papillomavirus genotypes. *J Cutan Med Surg.* 2002;6:117–21.
54. Yoneta A, Yamashita T, Jin HY, Iwasawa A, Kondo S, Jimbow K. Development of squamous cell carcinoma by two high-risk human papillomaviruses (HPVs), a novel HPV-67 and HPV-31 from Bowenoid papulosis. *Br J Dermatol.* 2000;143:604–8.
55. De Araújo LA, De Paula AAP, de Paula HDSC, Ramos JEP, de Oliveira BR, De Carvalho KPA, et al. Human papillomavirus (HPV) genotype distribution in penile carcinoma: association with clinic pathological factors. *PLoS One.* 2018;27; 13:e0199557.
56. Lazcano-Ponce E, Sudenga SL, Torres BN, Stoler M, León-Maldonado L, Allen-Leigh B, et al. Incidence of external genital lesions related to human papillomavirus among Mexican men. A cohort study. *Salud Publica Mex.* 2018;60:633–44.
57. Martínez-Bailón C, Mantilla-Morales A, Méndez-Matías G, Alvarado-Cabrero I, Maldonado-Rodríguez R, Quintero-Becerra J, et al. Human papillomavirus genotypes and P16INK4a expression in squamous penile carcinoma in Mexican patients. *BMC Infect Dis.* 2019;19:1068.

58. Prowse DM, Ktori EN, Chandrasekaran D, Prapa A, Baithun S. Human papilloma-virus-associated increase in p16INK4A expression in penile lichen sclerosus and squamous cell carcinoma. *Br J Dermatol.* 2008;158:261–5.
59. Fernández-Nestosa MJ, Guimerà N, Sanchez DF, Cañete-Portillo S, Velazquez EF, Jenkins D, et al. Human papillomavirus (HPV) genotypes in condylomas, intraepithelial neoplasia, and invasive carcinoma of the penis using laser capture microdissection (LCM)-PCR: a study of 191 lesions in 43 patients. *Am J Surg Pathol.* 2017;41:820–32.
60. Krustrup D, Jensen HL, van den Brule AJ, Frisch M. Histological characteristics of human papilloma-virus-positive and -negative invasive and in situ squamous cell tumours of the penis. *Int J Exp Pathol.* 2009;90:182–9.
61. Heideman D, Waterboer T, Pawlita M, van Diemen P, Nindl I, Leijte J, et al. Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. *J Clin Oncol.* 2007;25:4550–6.